Skip to main content
SpringerLink
Log in

Development of Inhibitors of HER2 With Taxanes

  • Chapter
Combination Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 534 Accesses

Abstract

The development of superior treatment strategies directed against metastatic breast cancer remains a major challenge. Because this condition is historically treatable but not curable, the primary goal of clinical management is often to create an optimal equilibrium between maximizing response, minimizing toxicity, improving survival, and optimizing symptom palliation. The search for new drugs that might provide these characteristics, together with an expanding understanding of the molecular basis of cancer, has prompted the development and investigation of “biologic” agents, which offer high tumor selectivity together with a favorable therapeutic ratio.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Stern DF, Heffernan PA, Weinberg RA. p185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 1986;6(5):1729–1740.

    PubMed  CAS  Google Scholar 

  2. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986;319:226–230.

    Article  Google Scholar 

  3. Pinkas-Kramarski R, Shelly M, Guarino BC, et al. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 1998;18:6090–6101.

    PubMed  CAS  Google Scholar 

  4. Padhy LC, Shih C, Cowing D, et al. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 1982;28:865–871.

    Article  PubMed  CAS  Google Scholar 

  5. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.

    Article  PubMed  CAS  Google Scholar 

  6. Press MF, Cordon-Cardo C, Slamon DJ: Expression of the HER2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953–962.

    PubMed  CAS  Google Scholar 

  7. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–181.

    Article  PubMed  CAS  Google Scholar 

  8. Hudziak RM, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165–1172.

    PubMed  CAS  Google Scholar 

  9. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829–1838.

    PubMed  CAS  Google Scholar 

  10. Mass R. The role of HER2 expression in predicting response to therapy in breast cancer. Sem Oncol 2000;27(6, Supp 11):46–52.

    CAS  Google Scholar 

  11. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737–744.

    PubMed  CAS  Google Scholar 

  12. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285–4289.

    Article  PubMed  CAS  Google Scholar 

  13. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.

    PubMed  CAS  Google Scholar 

  14. Vogel CL, Cobleigh M, Tripathy D, et al. Superior outcomes with Herceptin (trastuzumab) in fluorescence in situ hybridization (FISH)-selected patients. Proc Am Soc Clin Oncol 2001;20, abstract 86.

    Google Scholar 

  15. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241–2251.

    Article  PubMed  CAS  Google Scholar 

  16. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu over-expressing human breast cancer xenografts. Cancer Res 1998;58:2825–2831,.

    PubMed  CAS  Google Scholar 

  17. Slamon, D J, Leyland-Jones, B, Shak, S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001;344:783–792.

    Article  PubMed  CAS  Google Scholar 

  18. Mass RD, Press M, Anderson S, et al. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 2001;20, abstract 85.

    Google Scholar 

  19. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587–2595.

    PubMed  CAS  Google Scholar 

  20. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004;22(14S):6s (abst 512).

    Google Scholar 

  21. Gelmon K, Arnold A, Verma S, et al. Pharmacokinetics and safety of trastuzumab when administered every three weeks to women with metastatic breast cancer. Proc Am Soc Clin Oncol 2001;abs 271.

    Google Scholar 

  22. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999;17(5):1413–1424.

    PubMed  CAS  Google Scholar 

  23. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17(8):2341–2354.

    PubMed  CAS  Google Scholar 

  24. Sjostrom J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999;35(8):1194–1201.

    Article  PubMed  CAS  Google Scholar 

  25. Konecny G, Pegram MD, Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER2/neu overexpression. Breast Cancer Res Treat 1999;57:114 (abst 467).

    Google Scholar 

  26. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(7):1800–1808.

    Article  PubMed  CAS  Google Scholar 

  27. Burris HA. Docetaxel plus trastuzumab in breast cancer. Sem Oncol 2001;28:38–44.

    Article  CAS  Google Scholar 

  28. Extra JM, Cognetti F, Chan S, et al. First-line trastuzumab plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer: results from a randomized phase II trial (M77001). Breast Cancer Res Treat 2003;82(suppl 1):S47 (abst 217).

    Google Scholar 

  29. Uber KA, Nicholson BP, Thor AD, et al. A phase II trial of weekly docetaxel and Herceptin as first-or second-line treatment in HER2 over-expressing metastatic breast cancer. Proc Am Soc Clin Oncol 2001;20:50b (abst 1949).

    Google Scholar 

  30. Meden H, Beneke A, Hesse T, et al. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res 2001;21(2B):1301–1305.

    PubMed  CAS  Google Scholar 

  31. Sparano JA, Malik U, Manalo J, et al. Phase II trial of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Breast Cancer Res Treat 2000;64:80 (abst 317).

    Google Scholar 

  32. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330(18):1260–1266.

    Article  PubMed  CAS  Google Scholar 

  33. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90(18):1346–1360.

    Article  PubMed  CAS  Google Scholar 

  34. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90(18):1361–1370.

    Article  PubMed  CAS  Google Scholar 

  35. Theodoulou M, Campos SM, Batist G, et al. TLC D99 and Herceptin is safe in advanced breast cancer: final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 2002;21:55a (abst 216).

    Google Scholar 

  36. Trigo J, Climent MA, Gil M, et al. Cardiac safety and activity of a phase I study of 3-weekly myocet in combination with weekly herceptin and paclitaxel in HER2-positive locally advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2002;21:61a (abst 242).

    Google Scholar 

  37. Steger GG, Wenzel C, Locker GJ, et al. Pilot trial of trastuzumab + weekly epidoxorubicin/docetaxel in the neoadjuvant treatment of primary breast cancer-preliminary results. Proc Am Soc Clin Oncol 2002;21:39b (abst 1966).

    Google Scholar 

  38. Buzdar AU, Hunt K, Smith T, et al. Signficantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab, paclitaxel, and anthracycline-containing chemotherapy: initial results of a randomized trial in operable breast cancer with HER2 positive disease. J Clin Oncol 2004;22(14S):7s (abst 520).

    Google Scholar 

  39. Pegram MD, Finn RS, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537–547.

    Article  PubMed  CAS  Google Scholar 

  40. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659–2671.

    PubMed  CAS  Google Scholar 

  41. Nabholtz JA, Reese DM, Lindsay M, et al. Docetaxel in the treatment of breast cancer: an update on recent studies. Sem Oncol 2002;29(3):28–34.

    Article  CAS  Google Scholar 

  42. Slamon D, Yeon CH, Pienkowski T, et al. Survival analysis from two open-label nonrandomized phase II trials of trastuzumab combined with docetaxel and platinums (cisplatin or carboplatin) in women with HER2+ advanced breast cancer. J Clin Oncol 2004;22(14S):37s (abst 642).

    Google Scholar 

  43. Brufsky A, Lebish J, Shanahan C, et al. Phase II trials of carboplatin/docetaxel and carboplatin/docetaxel/trastuzumab as first line therapy for metastatic breast cancer. Breast Cancer Res Treat 2000;64:81 (abst 321).

    Google Scholar 

  44. Perez EA, Rowland KM, Suman VJ, et al. N98-32-52: efficacy and tolerability of two schedules of paclitaxel, carboplatin, and trastuzumab in women with HER2 positive metastatic breast cancer: a North Central Cancer Treatment Group randomized phase II trial. Breast Cancer Res Treat 2003;82(suppl 1):S47 (abst 216).

    Google Scholar 

  45. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzmab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: an update including survival. Proc Am Soc Clin Oncol 2004;23:20 (abst 573).

    Google Scholar 

  46. Hurley J, Doliny P, Silva O, et al. Neoadjuvant herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol 2002;21:50a (abst 196).

    Google Scholar 

  47. Baselga J: A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. 2002;Cancer Cell 2(2):93.

    Article  PubMed  CAS  Google Scholar 

  48. Agus D, Akita R, Fox W, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2(2):127.

    Article  PubMed  CAS  Google Scholar 

  49. Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 2002;62:3132–3137.

    PubMed  CAS  Google Scholar 

  50. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002;21:1159–1166.

    Article  PubMed  CAS  Google Scholar 

  51. Nguyen DM, Lorang D, Chen A, et al. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 2001;72:371–379.

    Article  PubMed  CAS  Google Scholar 

  52. Wilson RH, Takimoto CH, Agnew EB, et al. Phase I pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced tumors. Proc Am Soc Clin Oncol 2001;20:82a.

    Google Scholar 

  53. Banerji U, O’Donnell A, Scurr M, et al. Phase I trial of the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG). Pharmacokinetic profile and pharmacodynamic endpoints. Proc Am Soc Clin Oncol 2001;20:82a.

    Google Scholar 

  54. Munster PN, Tong W, Schwartz L, et al. Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2001;20:83a.

    Google Scholar 

  55. Allen LF, Lenehan PF, Eiseman IA, Elliot WL, Fry DW. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Sem Oncol 2002;29(3 suppl 11):11–21.

    Article  CAS  Google Scholar 

  56. Rinehart JJ, Wilding G, Willson J, et al. A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002;21:11a.

    Google Scholar 

  57. Zhou H, Kim YS, Peletier A, et al. effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR-and HER2-overexpressing breast cancer cell proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004;58(2):344–352.

    Article  PubMed  CAS  Google Scholar 

  58. Foy TM, Fanger GR, Hand S, et al. Designing HER2 vaccines. Sem Oncol 2002;29(3):53–61.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Cancer Service, Memorial Sloan-Kettering Cancer Center, New York, NY

    Shanu Modi MD, Monica N. Fornier MD & Andrew D. Seidman MD

Authors
  1. Shanu Modi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica N. Fornier MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew D. Seidman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

    Gary K. Schwartz MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Modi, S., Fornier, M.N., Seidman, A.D. (2005). Development of Inhibitors of HER2 With Taxanes. In: Schwartz, G.K. (eds) Combination Cancer Therapy. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1385/1-59259-864-1:175

Download citation

  • DOI: https://doi.org/10.1385/1-59259-864-1:175

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-200-1

  • Online ISBN: 978-1-59259-864-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation